Sanofi announces positive data for frexalimab in relapsing MS
The neurological disease affects approximately 2.8 million people worldwide - News - PharmaTimes
Stay updated with breaking news from Multiple Sclerosis Centers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The neurological disease affects approximately 2.8 million people worldwide - News - PharmaTimes
Frexalimab, a Sanofi drug candidate with roots at Dartmouth’s medical school, has met the main goal of its Phase 2 test. The encouraging data for this program come as different experimental Sanofi MS drug nears its one-year anniversary under FDA clinical hold.
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...
Issuer: Immunic, Inc. / Key word(s): Conference Immunic to Participate in Scientific and Investor Conferences in June 30.05.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to Participate in Scientific and Investor Conferences in June NEW YORK,...
Issuer: Immunic, Inc. / Key word(s): Conference Immunic to Participate in Scientific and Investor Conferences in June 30.05.2023 / 12:30 CET/CEST The issuer is solely responsible